-
EP2927240
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2927240
| EP2927240 - COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 09.09.2016 Database last updated on 03.10.2024 | Most recent event Tooltip | 09.09.2016 | Application deemed to be withdrawn | published on 12.10.2016 [2016/41] | Applicant(s) | For all designated states MedImmune, LLC One MedImmune Way Gaithersburg, MD 20878 / US | [2015/50] |
| Former [2015/45] | For all designated states Medimmune, LLC One Medimmune Way Gaithersburg, Maryland 20878 / US | Inventor(s) | 01 /
Langermann, Solomon 6606 Cross Country Blvd. Baltimore, MD 21215 / US | 02 /
Liu, Linda 6512 Tipperary Ct. Clarksville, MD 21029 / US | [2015/41] | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [N/P] |
| Former [2015/41] | Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB | Application number, filing date | 15163742.8 | 25.08.2009 | [2015/41] | Priority number, date | US20080091709P | 25.08.2008 Original published format: US 91709 P | US20080091694P | 25.08.2008 Original published format: US 91694 P | US20080091705P | 25.08.2008 Original published format: US 91705 P | US20090211697P | 02.04.2009 Original published format: US 211697 P | [2015/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2927240 | Date: | 07.10.2015 | Language: | EN | [2015/41] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 09.09.2015 | Classification | IPC: | C07K14/47, C07K14/705, C07K14/52, C07K14/715, C12N15/62 | [2015/41] | CPC: |
A61K38/177 (EP,US);
A61K31/675 (EP,US);
A61K45/06 (EP,US);
A61P31/00 (EP);
A61P31/04 (EP);
A61P31/10 (EP);
A61P31/12 (EP);
A61P31/14 (EP);
A61P31/16 (EP);
A61P31/18 (EP);
A61P31/20 (EP);
A61P31/22 (EP);
A61P33/00 (EP);
A61P33/02 (EP);
A61P33/06 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P37/04 (EP);
A61P43/00 (EP);
C07K14/70532 (EP,US);
C07K2319/33 (EP,US);
Y02A50/30 (EP,US)
(-)
| C-Set: |
A61K31/675, A61K2300/00 (EP,US)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2015/41] | Extension states | AL | 15.04.2015 | BA | 15.04.2015 | RS | 15.04.2015 | Title | German: | PD1-ANTAGONISTENZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG | [2015/41] | English: | COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE | [2015/41] | French: | COMPOSITIONS D'ANTAGONISTES PD-1 ET PROCÉDÉS D'UTILISATION | [2015/41] | Examination procedure | 15.04.2015 | Examination requested [2015/41] | 08.04.2016 | Application deemed to be withdrawn, date of legal effect [2016/41] | 17.05.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2016/41] | Parent application(s) Tooltip | EP09811805.2 / EP2350129 | Fees paid | Renewal fee | 15.04.2015 | Renewal fee patent year 03 | 15.04.2015 | Renewal fee patent year 04 | 15.04.2015 | Renewal fee patent year 05 | 15.04.2015 | Renewal fee patent year 06 | 27.08.2015 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO9308120 (SPHINX PHARMA CORP [US]) [A] 1-18* the whole document *; | [A]WO03020259 (CANCER REC TECH LTD [GB], et al) [A] 1-18 * the whole document *; | [A]WO2006121168 (ONO PHARMACEUTICAL CO [JP], et al) [A] 1-18 * the whole document *; | [AD] - MACHIELS J-P H ET AL, "Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20010501), vol. 61, no. 9, ISSN 0008-5472, pages 3689 - 3697, XP002250898 [AD] 1-18 * the whole document * | by applicant | US5190929 | WO0114557 | WO02079499 | WO03099196 | WO2004004771 | WO2004056875 | WO2004072286 | US6803192 | WO2006012232 | US2006099203 | US2006110383 | US7052694 | US7105328 | WO2006121168 | WO2006133396 | WO2007005874 | WO2007056539 | US2007166281 | US2007202077 | US7390888 | WO2008083174 | US7411051 | US2008274490 | WO2009014708 | WO2009073533 | - LENSHOW ET AL., ANNU. REV. IMMUNOL.,, (1996), vol. 14, pages 233 - 258 | - CHAMBERS; ALLISON, CURR. OPIN. IMMUNOL., (1997), pages 396 - 404 | - RATHMELL; THOMPSON, ANNU. REV. IMMUNOL., (1999), vol. 17, pages 781 - 828 | - KRUMMEL; ALLISON, J. EXP. MED., (1996), vol. 183, pages 2533 - 2540 | - WALUNAS ET AL., J. EXP. MED., (1996), vol. 183, pages 2541 - 2550 | - DONG ET AL., NATURE MED., (1999), vol. 5, pages 1365 - 1369 | - FREEMAN ET AL., J. EXP. MED., (2000), vol. 192, pages 1 - 9 | - TSENG ET AL., J. EXP. MED., (2001), vol. 193, pages 839 - 846 | - LATCHMAN ET AL., NATURE IMMUNOL., (2001), vol. 2, pages 261 - 268 | - WANG ET AL., BLOOD, (2000), vol. 96, pages 2808 - 2813 | - SWALLOW ET AL., IMMUNITY, (1999), vol. 11, pages 423 - 432 | - YOSHINAGA ET AL., NATURE, (1999), vol. 402, pages 827 - 832 | - CHAPOVAL ET AL., NATURE IMMUNOL., (2001), vol. 2, pages 269 - 274 | - CHOI ET AL., J. IMMUNOL., (2003), vol. 171, pages 4650 - 4654 | - SICA ET AL., IMMUNITY, (2003), vol. 18, pages 849 - 861 | - PRASAD ET AL., IMMUNITY, (2003), vol. 18, pages 863 - 873 | - ZANG ET AL., PROC. NATL. ACAD. SCI. U.S.A., (2003), vol. 100, pages 10388 - 10392 | - SCHWARTZ ET AL., NATURE IMMUNOL., (2002), vol. 3, pages 427 - 434 | - WILLIAMS; BARCLAY, ANNU. REV. IMMUNOL., (1988), vol. 6, pages 381 - 405 | - OSTROV ET AL., SCIENCE, (2000), vol. 290, pages 816 - 819 | - SCHWART ET AL., NATURE, (2001), vol. 410, pages 604 - 608 | - STAMPER ET AL., NATURE, (2001), vol. 410, pages 608 - 611 | - IKEMIZU ET AL., IMMUNITY, (2000), vol. 12, pages 51 - 60 | - SCHWARTZ ET AL., NATURE, (2001), vol. 410, pages 604 - 608 | - BAJORATH ET AL., J. MOL. GRAPH. MODEL.,, (1997), vol. 15, pages 135 - 139 | - WAND ET AL., J. EXP. MED., (2002), vol. 195, pages 1033 - 1041 | - TAMURA, BLOOD, (2001), vol. 97, pages 1809 - 1816 | - FREEMAN ET AL., J. EXP. MED., (2000), vol. 192, pages 1027 - 1034 | - ISHIDA ET AL., EMBO J., (1992), vol. 11, pages 3887 - 3895 | - KEIR ET AL., CURR. OPIN. IMMUNOL., (2007), vol. 19, pages 309 - 314 | - WAHL ET AL., J. NUC. MED., (1983), vol. 24, pages 316 - 325 | - HOCHMAN, J. ET AL., BIOCHEMISTRY, (1973), vol. 12, pages 1130 - 1135 | - SHARON, J. ET AL., BIOCHEMISTRY, (1976), vol. 15, pages 1591 - 1594 | - ROUSSEAUX ET AL., METH. ENZYMOL.,, (1986), vol. 121, pages 663 - 69 | - KABAT ET AL., J. BIOL. CHEM., (1977), vol. 252, pages 6609 - 6616 | - FREEMAN, PROC. NATL. ACAD. SCI. U. S. A, (2008), vol. 105, pages 10275 - 10276 | - MOLNAR ET AL., "Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2", PNAS, (20080729), vol. 105, pages 10483 - 10488 | - ONLAMOON ET AL., IMMUNOLOGY, (2008), vol. 124, pages 277 - 293 | - PERTOVAS ET AL., J. EXP. MED., (2006), vol. 203, page 2281 | - NISHIMURA ET AL., IMMUNITY, (1999), vol. 11, pages 141 - 151 | - NISHIMURA ET AL., SCIENCE, (2001), vol. 291, pages 319 - 322 | - BUTTE ET AL., IMMUNITY, (2007), vol. 27, pages 111 - 122 | - LAZAR MOLNAR ET AL., PNAS, (2008), vol. 105, pages 10483 - 10488 | - BERGER ET AL., CLIN. CANCER RES., (2008), vol. 14, pages 3044 - 3051 | - ERBE ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 7363 - 7368 | - CUBILLOS-RUI ET AL., J. CLIN. INVEST., (2009), vol. 119, no. 8, pages 2231 - 2244 | - LIANG J; HUANG M; DUAN W; YU XQ; ZHOU S., "Design of new oxazaphosphorine anticancer drugs", CURR PHARM DES., (2007), vol. 13, no. 9, pages 963 - 78 | - LI ET AL., "Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy", CLIN CANCER RES., (20061115), vol. 12, no. 22, pages 6808 - 16 | - BRODE; COOKE, CRIT REV. IMMUNOL., (2008), vol. 28, pages 109 - 126 | - VAN DER MOST ET AL., CANCER IMMUNOL. IMMUNOTHER., (2009), vol. 58, pages 1219 - 1228 | - TAIEB,J., J. IMMUNOL., (2006), vol. 176, pages 2722 - 2729 | - BAS; MASTRANGELO, CANCER IMMUNOL. IMMUNOTHER., (1998), vol. 47, pages 1 - 12 | - MACHIELS ET AL., CANCER RES., (2001), vol. 61, pages 3689 - 3697 | - HENGST ET AL., CANCER RES., (1981), vol. 41, pages 2163 - 2167 | - HENGST, CANCER RES., (1980), vol. 40, pages 2135 - 2141 | - REMINGTON'S PHARMACEUTICAL SCIENCES, MACK PUB. CO. | - "Recombinant Gene Expression Protocols,", Methods in Molecular Biology, HUMANA PRESS, (1997), vol. 62 | - BRODE S; COOKE A, "Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide", CRIT REV.LMMUNOL., (2008), vol. 28, no. 2, pages 109 - 26 | - VAN DER MOST RG; CURRIE AJ; MAHENDRAN S; PROSSER A; DARABI A; ROBINSON BW; NOWAK AK; LAKE RA, "Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy", CANCER IMMUNOL.LMMUNOTHER., (200908), vol. 58, no. 8, pages 1219 - 28 | - TAIEB J; CHAPUT N; SCHARTZ N; ROUX S; NOVAULT S; MENARD C; GHIRINGHELLI F; TERME M; CARPENTIER AF; DARRASSE-JEZE G ET AL., "Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines", J.IMMUNOL., (20060301), vol. 176, no. 5, pages 2722 - 9 | - MACHIELS JP; REILLY RT; EMENS LA; ERCOLINI AM; LEI RY; WEINTRAUB D; OKOYE FL; JAFFEE EM, "Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice", CANCER RES., (20010501), vol. 61, no. 9, pages 3689 - 97 | - BASS KK; MASTRANGELO MJ, "Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer", CANCER IMMUNOL.IMMUNOTHER., (199809), vol. 47, no. 1, pages 1 - 12 | - HENGST JC; MOKYR MB; DRAY S, "Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors", CANCER RES., (198106), vol. 41, no. 6, pages 2163 - 7 | - HENGST JC; MOKYR MB; DRAY S, "Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice", CANCER RES., (198007), vol. 40, no. 7, pages 2135 - 41 | - TSUNG K; MEKO JB; TSUNG YL; PEPLINSKI GR; NORTON JA, "Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12", J.IMMUNOL., (19980201), vol. 160, no. 3, pages 1369 - 77 | - HONEYCHURCH J; GLENNIE MJ; LLLIDGE TM., "Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells", CANCER RES., (20050815), vol. 65, no. 16, pages 7493 - 501 | - WADA S; YOSHIMURA K; HIPKISS EL; HARRIS TJ; YEN HR; GOLDBERG MV; GROSSO JF; GETNET D; DEMARZO AM; NETTO GJ, "Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model", CANCER RES., (20090515), vol. 69, no. 10, pages 4309 - 18 | - FREEMAN,G.J, "Structures of PD-1 with its ligands: sideways and dancing cheek to cheek", PROC. NATL. ACAD. SCI. U. S. A, (2008), vol. 105, pages 10275 - 10276 | - BRODE,S; COOKE,A., "Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide", CRIT REV. IMMUNOL., (2008), vol. 28, pages 109 - 126 | - VAN DER MOST,R.G. ET AL., "Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy", CANCER IMMUNOL. IMMUNOTHER., (2009), vol. 58, pages 1219 - 1228 | - TAIEB,J. ET AL., "Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.", J. IMMUNOL., (2006), vol. 176, pages 2722 - 2729 | - BASS,K.K.; MASTRANGELO,M.J., "Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer", CANCER IMMUNOL. IMMUNOTHER., (1998), vol. 47, pages 1 - 12 | - MACHIELS,J.P ET AL., "Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice", CANCER RES., (2001), vol. 61, pages 3689 - 3697 | - HENGST,J.C.; MOKYR,M.B.; DRAY,S., "Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors", CANCER RES., (1981), vol. 41, pages 2163 - 2167 | - HENGST,J.C; MOKYR,M.B.; DRAY,S., "Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice", CANCER RES., (1980), vol. 40, pages 2135 - 2141 | - TSUNG,K.; MEKO,J.B.; TSUNG,Y.L; PEPLINSKI,G.R.; NORTON,J.A, "Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12", J. IMMUNOL., (1998), vol. 160, pages 1369 - 1377 | - HONEYCHURCH,J; GLENNIE,M.J.; ILLIDGE,T.M., "Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells", CANCER RES., (2005), vol. 65, pages 7493 - 7501 |